JPWO2019173587A5 - - Google Patents

Claims (43)

formula

[During the ceremony,
X is independently O or S;
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Are R ^3a and R ^4a independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
Compounds, or pharmaceutically acceptable salts thereof, tautomers or stereoisomers thereof. formula

[During the ceremony,
X is S;
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Are R ^3a and R ^4a independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is O;
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Are R ^3a and R ^4a independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Are R ^3a and R ^4a independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Are R ^3a and R ^4a independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is independently O or S;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Are R ^3a and R ^4a independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is S;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Are R ^3a and R ^4a independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is O;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Are R ^3a and R ^4a independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Are R ^3a and R ^4a independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Are R ^3a and R ^4a independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a or R ⁴ and R ^4a may independently and together form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is independently O or S;
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is S;
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is O;
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ and R ⁴ are independently H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is S;
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is O;
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X ¹ , X ² , X ³ and X ⁴ are independently O or NH;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is independently O or S;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ³ is H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Is R ^3a H, CH ₃ , Halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ³ and R ^3a may together form a 3- to 4-membered carbon ring; or
R ³ and R ^3a may be combined to form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

[During the ceremony,
X is independently O or S;
R ¹ and R ² are independent,

And;
However, one of R ¹ and R ²

Must be;
Each Z ¹ is independently N or CR ^a ;
Z ² is NR ^b ;
R ^a is H, halogen, 0-6 R ⁵ substituted C _1-6 alkyl, 0-6 R ⁵ substituted C _3-6 cycloalkyl, CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) ) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) ) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^b is H, C _1-6 alkyl substituted with 0-6 R ⁵ , C _3-6 cycloalkyl substituted with 0-6 R ⁵ , -C (O) R ^a1 ,- C (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^a1 is H, C _1-3 alkyl or C _3-6 cycloalkyl;
R ⁴ is H, CH ₃ , halogen, -NR ^a1 R ^a1 or OR ^a1 ;
Is R ^4a H, CH ₃ , Halogen, -NR ^a1 R ^a1 or OR ^a1 ;
R ⁴ and R ^4a may together form a 3- to 4-membered carbon ring; or
R ⁴ and R ^4a may be combined to form a C = CH ₂ substituent;
R ⁵ is H, halogen, C _1-3 alkyl substituted with 0-6 R ^a , C _3-6 cycloalkyl substituted with 0-6 R ^a , 0-6 R ^a . Aryl substituted with 0-6 R ^a , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC ( O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 ,- NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ^5a is a C _1-3 alkyl substituted with H or 0-6 R ^5s ;
R ⁶ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
R ⁸ is H, halogen, C _1-3 alkyl substituted with 0-6 R ⁵ , CN, NO ₂ , OH, OR ^a1 , SR ^a1 , -C (O) NR ^a1 R ^a1 , -COOR ^a1 , -OC (O) R ^a1 , -OC (O) NR ^a1 R ^a1 , -NR ^a1 R ^a1 , -NR ^a1 C (O) R ^a1 , -NR ^a1 COOR ^a1 , -NR ^a1 C (O) NR ^a1 R ^a1 , -NR ^a1 S (O) ₂ R ^a1 , -NR ^a1 S (O) ₂ NR ^a1 R ^a1 , -S (O) R ^a1 , -S (O) NR ^a1 R ^a1 , -S (O) ) ₂ R ^a1 or S (O) ₂ NR ^a1 R ^a1 ;
Each Y is independently CR ^a or N;
m is 0, 1, 2 or 3]
The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. formula

The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof.

The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof.

The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof.

The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof.

The compound of claim 1 or a pharmaceutically acceptable salt thereof, tautomer or stereoisomer thereof. 4-[(1R, 6R, 8R, 9R, 10R, 15R, 17S, 18R)-8- (6-amino-9H-purine-9-yl) -9-fluoro-18-hydroxy-3,12-dioxo -3,12-Disulfanyl- ^{2,4,7,11,13,16} -Hexaoxa-3λ 5,12λ ⁵ -Diphosphatricyclo [13.2.1.0 ^6,10 ] Octadecane-17-yl] Pyridine-2- Carboxamide,
4-[(1R, 6R, 8R, 9R, 10R, 15R, 17S, 18R) -8- (6-amino-9H-purine-9-yl) -9-fluoro-18-hydroxy-3,12-dioxo -3,12-disulfanyl- ^{2,4,7,11,13,16} -hexaoxa-3λ 5,12λ ⁵ -diphosphatricyclo [13.2.1.0 ^6,10 ] octadecane-17-yl] -N-methyl Pyridine-2-carboxamide, or
4-[(1R, 6R, 8R, 9R, 10R, 15S, 17S)-8- (6-amino-9H-purine-9-yl) -9-fluoro-18-methidene-3,12-dioxo-3 , 12-disulfanyl- ^{2,4,7,11,13,16} -hexaoxa-3λ 5,12λ ⁵ -diphosphatricyclo [13.2.1.0 ^6,10 ] octadecane-17-yl] pyridine-2-carboxamide,
4-[(1S, 6R, 8R, 9R, 10R, 15R, 17S, 18R)-8- (6-amino-9H-purine-9-yl) -9,18-difluoro-3,12-dioxo-3 , 12-disulfanyl- ^{2,4,7,11,13,16} -hexaoxa-3λ 5,12λ ⁵ -diphosphatricyclo [13.2.1.0 ^6,10 ] octadecane-17-yl] pyridine-2-carboxamide,
4-[(1R, 6R, 8R, 9R, 10R, 15R, 17S, 18R)-9-fluoro-18-hydroxy-8- {3H-imidazole [2,1-f] purin-3-yl} -3 , 12-Dioxo-3,12-Disulfanyl- ^{2,4,7,11,13,16} -Hexaoxa-3λ 5,12λ ⁵ -diphosphatricyclo [13.2.1.0 ^6,10 ] Octadecane-17-yl] The compound according to claim 1, which is pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof , a tautomer or a stereoisomer thereof. The compound according to any one of claims 1 to 27 or a pharmaceutically acceptable salt thereof , a tautomer or a stereoisomer , and one or more pharmaceutically acceptable carriers, diluents or excipients. A pharmaceutical composition comprising an agent. A pharmaceutical composition comprising the compound according to any one of claims 1 to 27 or a pharmaceutically acceptable salt thereof , a tautomer or a stereoisomer for use with one or more other therapeutically active agents. A pharmaceutical composition comprising the compound according to any one of claims 1 to 27 or a pharmaceutically acceptable salt thereof , a tautomer or a stereoisomer for treatment. The compound according to any one of claims 1 to 27 , a pharmaceutically acceptable salt thereof, or a tautomer for use in the treatment of a disease or condition that may be alleviated by inducing an immune response via the STING pathway. Alternatively, a pharmaceutical composition comprising a stereoisomer . The pharmaceutical composition according to claim 31, wherein the disease or condition is cancer. The compound according to any one of claims 1 to 27 or a pharmaceutically acceptable salt thereof , a tautomer or a stereoisomer thereof in the manufacture of a therapeutic agent for a disease or condition for which adjustment of STING has been shown. use. A compound according to any one of claims 1 to 27 or a pharmaceutically acceptable salt thereof , a tautomer or a stereoisomer thereof for treating a disease and a medical condition for which adjustment of STING has been shown. Including, pharmaceutical composition . A pharmaceutical composition comprising one or more of the compound according to any one of claims 1 to 27 or a pharmaceutically acceptable salt thereof , a tautomer or a stereoisomer for treating cancer. The cancers are small cell lung cancer, non-small cell lung cancer, colon cancer, melanoma, renal cell cancer, head and neck cancer, hodgkin lymphoma, bladder cancer, esophageal cancer, gastric cancer, ovarian cancer, cervical cancer, pancreatic cancer, Prostate cancer, breast cancer, urinary cancer, brain tumor (eg, glial bud), non-hodgkin lymphoma, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) ), Hepatic cell carcinoma, multiple myeloma, gastrointestinal stromal tumor, mesopharyngeal tumor, and other solid tumors or other blood cancers, claim 35. 36. The pharmaceutical composition of claim 36, wherein the cancer is small cell lung cancer, non-small cell lung cancer, colon cancer, melanoma, renal cell cancer, head and neck cancer, Hodgkin lymphoma or bladder cancer. The compound according to any one of claims 1 to 27 , or a pharmaceutically acceptable salt thereof , which is administered in combination with one or more immunotumor agents for treating cancer. A pharmaceutical composition comprising a body or stereoisomer . 38. The pharmaceutical composition of claim 38, wherein the immunotumor agent is ipilimumab. 38. The pharmaceutical composition of claim 38, wherein the immunotumor agent is a PD-L1 antagonist. A pharmaceutical composition comprising the compound according to any one of claims 1 to 27 for treating cancer , or a pharmaceutically acceptable salt thereof, a tautomer or a stereoisomer thereof.
a) The pharmaceutical composition and
b) An antibody that specifically binds to the Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity, or an anticancer drug that is an antigen-binding site thereof.
, A pharmaceutical composition . The pharmaceutical composition of claim 41, wherein the anti-PD-1 antibody is nivolumab or pembrolizumab. The pharmaceutical composition of claim 42, wherein the anti-PD-1 antibody is nivolumab.